GettyImages-182157308-correctedligtscreenWithchestxxray.jpg
CA2_5031_Genevieve de Manio Photogrpahy_Arsanis 2016.05.19.jpg
GettyImages-182157308-correctedligtscreenWithchestxxray.jpg

Addressing the Most Critical Infectious Disease Threats with Targeted Monoclonal Antibodies


 

 

SCROLL DOWN

Addressing the Most Critical Infectious Disease Threats with Targeted Monoclonal Antibodies


 

 

Our current programs address specific pathogens and their pathogenic processes selectively rather than broadly eliminating bacteria, potentially allowing Arsanis to combat critical infections without contributing to antibiotic resistance or damaging the patient’s microbiome.
 


featured news


CA2_5031_Genevieve de Manio Photogrpahy_Arsanis 2016.05.19.jpg

For Investors & Partners


Arsanis is uniquely positioned to discover and develop novel monoclonal antibodies to treat serious infectious diseases.

Download our Corporate Presentation

SCROLL DOWN

For Investors & Partners


Arsanis is uniquely positioned to discover and develop novel monoclonal antibodies to treat serious infectious diseases.

Download our Corporate Presentation